Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a treatment for autoimmune diseases, including systemic lupus erythematosus (SLE), that are associated with a very severe prognosis. We describe a 27-year-old woman with SLE with a 10-year history of refractory antiphospholipid syndrome (APS). She developed progressive myocardial necrosis despite treatment with corticosteroids, cyclophosphamide (CYC), cyclosporine, and immunopheresis. After conditioning with CYC, fludarabine, and antithymocyte globulin, autologous HSCT using CD34 þ selection was performed. After transplantation, the clinical symptoms caused by APS remitted, and the serum anticardiolipin antibody level decreased. Remission has persisted for 21 months after transplantation. Although a longer follow-up is required for the assessment of efficacy, autologous HSCT may cure patients with refractory APS.
stem cell transplantation; myocardial necrosis; systemic lupus erythematosus Antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses and recurrent fetal loss in the presence of antiphospholipid antibodies (aPL), and it frequently accompanies systemic lupus erythematosus (SLE). 1 Treatment with anticoagulation is generally initiated for APS. Although temporary elimination or reduction of aPL may be accomplished by several therapeutic regimens, including high-dose corticosteroids, immunosuppression, or immunopheresis in APS, antibodies return rapidly on cessation of therapy. 2, 3 Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a treatment for autoimmune diseases, including SLE that are associated with a very severe prognosis. [4] [5] [6] We report a 27-year-old patient with SLE with refractory APS and severe myocardial necrosis, who achieved a prolonged remission following CD34
þ -selected autologous HSCT. To our knowledge, this is the first report of refractory APS treated successfully with autologous HSCT.
Case report
The patient, a 27-year-old woman with SLE, had disease onset at the age of 17 with symptoms of polyarthritis, transient visual disturbance, precordial discomfort, and palpitations. Laboratory data were: hemoglobin (Hb) 9.6 g/dl, white blood cell count (WBC) 3.2 Â 10 9 /l, and platelet count 217 Â 10 9 /l; antinuclear antibodies (ANAs) and anti-DNA antibodies were positive, and serum C3, C4, and CH50 (50% hemolytic unit of complement) levels were decreased to 21, 3 mg/dl, and 7 U/ml, respectively. Anticardiolipin antibodies (aCL) were positive. Electrocardiographic (ECG) examination demonstrated ischemic changes, but echocardiography and myocardial scintigraphy were normal. The diagnosis of SLE and APS was made; maintenance oral corticosteroids and cyclosporine, plus a single infusion of cyclophosphamide (CYC) 10 mg/kg and immunopheresis, were initiated with partial improvement of her systemic illness and laboratory data.
During follow-up (1992-1999), the patient developed superficial venous thrombosis and livedo reticularis, and received oral corticosteroids and monthly plasmapheresis to prevent symptoms of APS. In March 1999, plasmapheresis was discontinued because of occlusion of the venous shunt. Treatment with oral corticosteroids and CYC were ineffective, resulting in an increase in the serum level of aCL. In January 2001, echocardiography and myocardial scintigraphy revealed abnormal left ventricular wall motion and ischemic changes of the lower ventricle. Angiography revealed decreased motion of the inferior wall, but coronary arteries were unaffected. Biopsy revealed myocardial necrosis compatible with myocardial damages caused by APS (Figure 1) .
Based on the progressive nature of her cardiac disease, which occurred despite intensive immunosuppressive treatment and frequent plasmapheresis, the patient was considered for autologous HSCT. After extensive crossconsultation, ethics committee approval, and informed consent, autologous HSCT was carried out in December 2001. In order to mobilize hematopoietic progenitor cells into peripheral blood, she received chemotherapy that consisted of etoposide at a dose of 4.8 mg/kg (1.6 mg/kg Â 3 days), followed by administration of granulocyte colonystimulating factor (G-CSF) at a dose of 10 mg/kg/day for 11 days. Leukapheresis was performed on days 12 and 13. To reduce the number of re-infused lymphocytes, T-cell depletion was performed as a positive selection of CD34 þ cells using the Isolex system (Isolex 300I, Nihon Kohden, Japan), and purified CD34 þ cells were subsequently cryopreserved in liquid nitrogen. The pretransplantation conditioning regimen was fludarabine at a dose of 0.8 mg/ kg for 5 days, CYC at a dose of 72 mg/kg for 2 days, and antithymocyte globulin (ATG) (Lymphoglobuline, Aventis) at a dose of 6 mg/kg for 2 days. After thawing, the total infused CD34 þ cell count was 4.1 Â 10 6 /kg and the contaminated T-lymphocyte dose was 3 Â 10 4 /kg. G-CSF was administered after transplantation at a dose of 10 mg/ kg/day for 15 days.
An absolute neutrophil count 40.5 Â 10 9 /l and platelet count 420 Â 10 9 /l were observed on day 12 after HSCT. Serum aCL and anticardiolipin b2GPI antibodies (aCLb2GPI) decreased from 84.2 to 25.5 U/ml (normal o10 U/ml) and from 17.5 to 2.8 U/ml (normal o3.5 U/ml), respectively, at 6 months after autologous HSCT. She experienced no recurrent symptoms caused by APS. Echocardiography and myocardial scintigraphy revealed improvement of the left ventricular wall motion and of ischemic changes of the lower ventricles, although ischemic ECG changes did not improve at 12 months after autologous HSCT. The remission state has persisted for 21 months of follow-up with a small dose of oral corticosteroids (prednisolone 10 mg) ( Table 1) . Table 2 shows the percentage of circulating lymphocyte subsets and the lymphocyte proliferative responses observed following transplantation. Immunologic reconstitution following HSCT was rapid for T cells, followed by B-cell reconstitution. However, full recovery of T-cell proliferative responses and CD4 þ T-cell reconstitution was not observed until 6 months after transplantation. Analysis of cytoplasmic T-helper type 1 (Th1) and Th2 cytokines in CD4 þ T cells revealed significant skewing to Th1 after autologous HSCT (Table 2) .
Discussion
We report the first case of a patient suffering from refractory APS, who was successfully treated with CD34 þ -selected autologous HSCT. Our patient had a 10-year history of APS resistant to aggressive immunosuppressive therapy and frequent immunopheresis. Moreover, she was experiencing progressive myocardial necrosis caused by APS.
Cardiac manifestations of APS included left-sided valvular insufficiency, intramyocardial arteriolar thrombosis, and coronary artery occlusion. Our patient had a long history of cardiac symptoms such as precordial discomfort and palpitations. She eventually developed abnormal left ventricular wall motion and ischemic changes caused by myocardial necrosis. Widespread acute intramyocardial arteriolar thrombosis, without evidence of vasculitis, is responsible for extensive muscle necrosis in patients with aPL. 7 Although the biopsy specimen of our patient did not show intramyocardial arteriolar thrombosis, it may be possible that the process is not acute but recurrent, and affects small groups of vessels, resulting in a clinical picture and a course similar to a chronic cardiomyopathy. Myocardial involvement is also known in patients with SLE without APS. However, the biopsy specimen of our patient did not show perivascular infiltration with lymphocytes and neutrophils, which is often observed in SLE patients. 8 These findings suggest that myocardial necrosis observed in our patient is due to APS. CD34 þ -selected autologous HSCT associated with infusion of ATG resulted in a dramatic decrease in serum aCL and aCLb2GPI levels, and improvement in clinical symptoms, which has persisted in the absence of intensive immunosuppressive therapy, except for low-dose corticosteroids.
In the European Group for Blood and Marrow Transplantation registry, CYC was the most frequent regimen for mobilization and pretransplantation conditioning. Since our patient was refractory to CYC therapy during follow-up, we used chemotherapy that consisted of etoposide for mobilization of hematopoietic progenitor cells. The pretransplantation conditioning regimen consisted of fludarabine and CYC (total dose of CYC was reduced to 144 mg/kg). We used CYC for the pretransplantation conditioning regimen because: (1) although our patient was refractory to CYC therapy during follow-up, CYC has a potent immunoablative effect and is the most standard regimen for pretransplantation conditioning, (2) although a single infusion of CYC (10 mg/kg) was not sufficient for the treatment of APS during follow-up, we observed a partial response. Therefore, it is possible that high-dose CYC (144 mg/kg) is effective for immunoablation. To potentiate the immunoablative effect, we included ATG in the pretransplantation conditioning regimen. The rationale for autologous HSCT in autoimmune diseases lies in the hypothesis that vigorous immunoablation can delete the autoreactive lymphocyte clone. Relapses have been reported in patients suffering from various autoimmune diseases, who were treated with unmanipulated autologous bone marrow or mobilized peripheral blood cells, 9 and in patients who developed serum sickness and therefore received only a small fraction of ATG. 10 Generally, autografts of at least 3.0 Â 10 6 CD34 þ cells/kg are recommended, although the required dose varies from protocol to protocol. A total of 10 5 /kg T cells (obtained by CD34 þ cell selection) has been suggested as the maximum number of re-infused T cells in manipulated grafts. 11 In our case, the total infused CD34 þ cell count was 4.1 Â 10 6 /kg and contaminated T-lymphocyte dose was 3 Â 10 4 /kg. Analysis of Th1 and Th2 revealed significant skewing to Th1 after autologous HSCT. Supporting our findings, a marked Th1 increase in parallel with an increase in lymphocytes was observed at 28 days after autologous HSCT from non-Hodgkin's lymphoma, suggesting that the Th1 recover dominantly after autologous HSCT. 12 Interestingly, serum aCL and Th2 remained low after transplantation, although the number of B and T cells recovered to the levels before transplant. Although the mechanisms of post transplant disease stabilization and improvement remain obscure, genetic makeup and environmental exposure play critical roles in autoimmune diseases. In fact, the concept of an environmental trigger and latent period are important in the rationale of autologous HSCT as a treatment of autoimmune diseases. Theoretically, high-dose immunosuppressive therapy with autologous HSCT has the potential to 'time shift' the clinical autoimmune disease line to an earlier period analogous to the latent period, restoring self-tolerance. 13 In phase I-II studies on feasibility, the investigators used selection criteria based on severe disease, progression despite available therapy, and lack of infection or organ damage that would preclude transplantation. In SLE, the inclusion criteria include catastrophic APS or failed CYC for glomerulonephritis (World Health Organization class III-IV), CNS lupus, vasculitis involving the heart or lung, or life-threatening cytopenia.
14 Although our patient did not develop catastrophic APS, we considered her for autologous HSCT based on the progressive nature of her cardiac disease, despite intensive immunosuppressive treatment.
There are several reports of SLE patients who have had improvement in the systemic lupus erythematosus disease activity index (SLEDAI) score, decreased antinuclear and anti-dsDNA antibody titers, decreased proteinuria, increased FVC, normalization of representative Th2 and Th1 cytokines, and normalization of T-cell repertoire after transplantation. [4] [5] [6] The potential role of T cells in the development and transfer of experimental primary APS and the treatment effect of HSCT on APS in a murine model have been reported. 15 Disappearance of the lupus anticoagulant has also been reported in a chronic myeloid leukemia patient who received allogeneic HSCT. 16 However, this is the first case to show decreased aCL titers and improved clinical symptoms of APS after autologous HSCT. The present case suggests the efficacy of autologous HSCT for patients with refractory APS.
